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Abstract
Background: Cambodia has made notable progress in the fight against tuberculosis (TB). However, these gains are
impeded by a significant proportion of undiagnosed cases. To effectively reach people with TB, active case-finding
(ACF) strategies have been adopted by countries affected by the epidemic, including Cambodia, alongside passive
case finding (PCF). Despite increased efforts to improve case detection, approximately 40% of TB cases in Cambodia
remained undiagnosed in 2018. In Cambodia, several community-based TB ACF modalities have been
implemented, but their effectiveness has yet to be systematically assessed.
Methods: This pragmatic cluster randomized controlled trial will be conducted between December 2019 and June
2021. We will randomize eight operational districts (clusters) in seven provinces (Kampong Cham, Kampong Thom,
Prey Veng, Thbong Khmum, Kampong Chhnang, Kandal, and Kampong Speu) to either the control group (PCF) or
the intervention groups (ACF using a seed-and-recruit model, ACF targeting household and neighborhood
contacts, and ACF targeting persons aged ≥ 55 years using mobile screening units). The primary endpoints will be
TB case notification rates, additionality, and cumulative yield of TB cases. The secondary endpoints include
treatment outcomes, the number needed to screen to find one TB case, and cost-effectiveness outcome measures.
We will analyze the primary and secondary endpoints by intention to treat. We will compare cluster and individual-
level characteristics using Student’s t test and hierarchical or mixed-effect models to estimate the ratio of these
means. The incremental cost-effectiveness ratio per disability-adjusted life year averted will also be considered as a
benchmark to determine whether the interventions are cost-effective.
Discussion: This study will build an evidence base to inform future scale-up, implementation, and sustainability of
ACF strategies in Cambodia and other similar settings. Implementation of this study will also complement TB
control strategies in Cambodia by conducting ACF in operational districts without active interventions to find TB
cases currently. Those who are ill and might have TB will be promptly screened, diagnosed, and linked to care. Early
diagnosis and treatment initiation will also benefit their community by interrupting transmission and prevent
further infections. The experience gained from this project will inform future attempts in conducting pragmatic
trials in low-resource settings.
Trial registration: ClinicalTrials.gov, NCT04094350. Registered on 18 September 2019.
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Introduction
Background and rationale
Cambodia is one of the countries with a high tubercu-
losis (TB) burden, with an estimated incidence of active
TB of 302 (95% CI: 169–473) per 100,000 population in
2018 [1]. Over the years, the country has made notable
progress in the fight against TB. In 2016, the TB inci-
dence was approximately half of that in 2000, and a
similar decline was observed in the TB mortality rate [2].
Cambodia also recorded a TB treatment success rate of
94%, one of the highest among the 30 countries with a
high TB burden [3]. However, the successes are encum-
bered by a significant proportion of undiagnosed cases.
Globally, it is estimated that 30% of TB cases were un-
diagnosed in 2018 [1]. Similarly, approximately 40% of
TB cases goes undetected in Cambodia [2]. Each missing
case continues to perpetuate the transmission of TB and
contribute to the current TB burden, compounding the
challenge to end TB. Houben and Dodd estimated that
60% of Cambodia’s population in 2014 were infected
with latent TB [4]. As the population ages over time, it
is projected that the prevalence of active TB will increase
[5]. Therefore, it is pertinent to reach TB-affected indi-
viduals and ensure accountable and effective TB treat-
ment to break the cycle of TB transmission.
Acceleration of efforts to find TB cases and narrowing
the gap in diagnosis is one way to reduce the TB burden
in Cambodia [5].
Traditionally, TB cases are reported and passively noti-
fied when people with TB present themselves to a health
facility. Active case finding (ACF), a proactive TB case-
finding approach, has been adopted by countries affected
by the epidemic, including Cambodia, to effectively
reach people with TB [6–8]. Current evidence suggests
that TB case-finding interventions at the community
level may increase TB case detection [8]. In Zimbabwe,
Corbett et al. demonstrated that ACF using a mobile van
approach resulted in a higher yield of smear-positive TB
cases compared to ACF conducted via door-to-door
visits [9]. The prevalence of smear-positive TB also de-
clined significantly during the intervention period, sug-
gesting that ACF could interrupt TB transmission [9]. In
Vietnam, a household-contact investigation was reported
to be more effective than standard passive case finding
alone for the detection of TB [10]. However, despite in-
creased efforts to improve case detection, integrating TB
case finding in health-care systems remains a great chal-
lenge in diverse socioeconomic, geographical, epidemio-
logic, and other sociocultural contexts [11, 12].
Cambodia has achieved a significant reduction in TB
burden through patient-centered approaches, strong
community mobilization, and decentralization of TB
care to the primary level of health care to reach under-
served communities [13, 14]. Within the rubric of
community TB care, the national TB program (NTP)
has implemented several successful models of TB case-
finding initiatives in collaboration with civil society orga-
nizations. Under a community TB screening approach,
household and other close contacts of people with
smear-positive TB were referred to health centers and
screened using a TB symptoms questionnaire and chest
X-ray (CXR). This approach has been shown to increase
TB case notifications by 65% compared to historical
baseline cases in the preceding year [7]. Economic ana-
lyses have also suggested that this approach is cost-
effective across a range of parameters such as numbers
of people screened and the yield of TB cases [15]. In an-
other model, one-off ACF using mobile diagnostic units
(GeneXpert and CXR) focused on people aged ≥ 55 years
has also been reported to increase the yield of TB diag-
noses and improve treatment outcomes [16].
To further reduce the TB burden, efforts should be
strengthened through systematic engagements with
groups at disproportionate risk for TB [17]. The NTP in
Cambodia has since recalibrated its focus to direct com-
munity TB activities at key affected populations (KAPs)
to accelerate TB case detection. In the Cambodian con-
text, the KAPs for TB identified by the NTP are people
aged 55 years and older, people living with HIV, close
contacts of people with smear-positive TB, prisoners,
people with diabetes, and people who use drugs [18]. To
effectively reach KAPs for TB, a community-based
snowball approach (seed-and-recruit mechanism) has
been recently implemented. Empirically, a peer-led ap-
proach as such has been widely accepted to reach con-
cealed populations, such as populations who are at risk
for HIV in many countries, including Cambodia, due to
its practical feasibility, and successes have been reported
[19–21]. The seed-and-recruit model, piloted in 2018 in
Cambodia, is well received and deemed feasible by the
beneficiaries and key stakeholders [22]. Preliminary ana-
lyses of the effectiveness of the model showed a 97% in-
crease in the yield of TB diagnoses (unpublished data; Ly
C, personal communication, June 5, 2019) compared to
historical baseline in the previous year.
At present, little is understood about how to best
apply and integrate ACF in the existing health-care sys-
tems in diverse epidemiologic, socioeconomic, and cul-
tural contexts [12]. In Cambodia, the different ACF
strategies—community seed-and-recruit mechanism,
contact investigations and referrals, one-off roving ACF
using mobile diagnostic tools—have been empirically
shown superior to passive case finding (PCF), but the ef-
fectiveness of these approaches in improving TB case de-
tection has yet to be systematically assessed. Moreover,
there is still insufficient evidence on the effect of ACF
on treatment [8] and the cost-effectiveness outcomes of
ACF in different settings [11].
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Objectives
The primary aim of this study is to evaluate the effect-
iveness of ACF strategies in increasing the yield of TB
diagnoses and case notifications in Cambodia. This study
also aims to establish the effect of ACF strategies on TB
treatment outcomes and to establish the number needed
to screen to detect one TB case. Lastly, this study aims
to estimate the cost-effectiveness of the interventions by
measuring the cost per TB case identified and the incre-
mental cost-effectiveness ratio.
Trial design
We will conduct a pragmatic cluster randomized con-
trolled trial with four arms comparing ACF with a seed-
and-recruit model, ACF targeting household and neigh-
borhood contacts, ACF targeting the older population
using mobile screening units, and a PCF approach in
eight operational districts (ODs) in Cambodia (Fig. 1).
These case-finding strategies have been piloted in
Cambodia, and the interventions will be carried out as
per the protocol devised by the partner organizations,
respectively. Target populations and presumptive TB
cases will be evaluated clinically, with CXR and/or with
bacteriological testing of sputum using either smear mi-
croscopy or the GeneXpert system, according to the na-
tional TB guideline [23]. A pragmatic cluster design was
chosen because the interventions will be conducted at
the community (collective) level in a “real-world” setting
for the avoidance of contamination, and it is not
practically possible to randomize the interventions at an
individual level.
Methods: participants, interventions, and
outcomes
Study setting
The sampling frame consisted of operational districts
(ODs) without ACF interventions currently, and in the
preceding 6 months from the project implementation
date. Using data from the Demographic Epidemiological
Model of Cambodia developed in collaboration with the
National Center for Tuberculosis and Leprosy Control
(CENAT) [5] and other health and demographic data
from Cambodia [24, 25], eight ODs (Fig. 1) have been
purposively selected to include ODs with high and low
incidence to maintain as much balance as possible. The
selection was also based on the number of health centers
to increase the comparability and generalizability of
study findings across the groups.
Eligibility criteria
In this study, an individual will be defined as presump-
tive TB if he/she exhibits any of the following symptoms
[26]:
 Pulmonary TB: a cough for more than 2 weeks and
at least one general symptom
 Extra-pulmonary TB: presence of symptoms,
depending on the location of TB (e.g., enlarged
Fig. 1 Trial profile. A pragmatic cluster randomized controlled trial with four arms comparing active case finding (ACF) with the seed-and-recruit
model, ACF targeting household and neighborhood contacts, ACF targeting the older population using mobile diagnostic units, and passive case
finding in eight operational districts in Cambodia. TB tuberculosis
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lymph node, swollen backbone, swollen articulation,
etc.), and at least one general symptom
 General symptoms: fever, night sweats for more
than 2 weeks, or unintentional weight loss (> 5%
reduction in usual body weight over the last 6–12
months) [27]
Presumptive TB cases will be referred to the health
centers for TB screening and diagnosis in the interven-
tion arms and self-presented to the health centers in the
control arm. We will include the aggregated number of
cases diagnosed and notified from all arms regardless of
age. However, we will only recruit people aged 18 years
or older with TB (all forms) for the baseline and follow-
up surveys and assessment of TB treatment outcomes.
Who will take informed consent?
Data collectors (project staff from Cambodian Anti-
Tuberculosis Association (CATA), KHANA, CENAT,
and/or health center staff) will be trained to explain the
study to the participants, obtain written consent for the sur-
veys (Additional file 2), and administer the questionnaire.
The data collectors will brief participants on the nature and
purpose of the study and potential risks, and will highlight
that information will be kept confidential. Consent will be
taken by the data collectors in a private space at the re-
spective OD after randomization. For participants who can-
not read or write, verbal consent will be taken, and this will
be noted by the consent taker on the consent form.
Additional consent provisions for collection and use of
participant data and biological specimens
No biological samples will be collected for research pur-
poses; hence, no additional consent will be sought from
the participants. Biological samples will be collected as
part of standard care (e.g., TB diagnosis and case man-
agement) defined in the national TB guideline under the
purview of the NTP.
Interventions
Explanation for the choice of comparators
The PCF strategy is a default setup in the national health
system. PCF is a patient-initiated pathway that relies on
the self-presentation of presumptive TB cases to the
health centers to be diagnosed with TB. Upon screening
by health center staff, sputum samples from presumptive
TB cases belonging to the KAPs will be collected for
examination by GeneXpert or direct smear microscopy
if the GeneXpert system is not available. CXR will be
performed at the referral hospital if the sputum examin-
ation result is negative. TB diagnoses will be made by
clinicians based on clinical, radiological, and microbio-
logical evidence. For presumptive TB individuals who
present with cough for less than 2 weeks, CXR will be
performed at the referral hospital, and sputum samples
will be collected for GeneXpert testing if radiological ab-
normalities are detected [23]. For presumptive TB cases
who do not belong to KAPs, smear examination will be
performed if presenting with a cough lasting for 2 weeks
or more. Those presenting to the health centers with
cough for less than 2 weeks will be referred to the refer-
ral hospital for CXR, and cases with any radiological ab-
normalities will undergo smear examination [23]. Newly
diagnosed people with TB will be treated and managed
according to the national TB guidelines. We will follow-
up all people with TB diagnosed during the study period
for 6 months from the treatment initiation.
This is a patient-initiated pathway to TB diagnosis in-
volving: a person with active TB experiencing symptoms
that he or she recognizes as serious; a person having ac-
cess to and seeking care, and presenting spontaneously at
an appropriate health facility; a health worker correctly
assessing that the person fulfills the criteria for presump-
tive TB; and the successful use of a diagnostic algorithm
with sufficient sensitivity and specificity to diagnose TB.
Intervention description
Intervention 1: ACF with the seed-and-recruit model
In the intervention clusters, a lay counselor appointed to a
health center will act as focal point for identifying potential
seeds (TB survivors and their family members and other
key informants in the community, such as moto-taxi
drivers and grocery store owners), screening presumptive
TB cases using a screening questionnaire, and training
seeds and recruiters to find other presumptive TB cases in
the community. Each lay counselor will be tasked to iden-
tify at least five seeds per health center to identify pre-
sumptive TB cases (recruits) in their community. These
recruits will be screened for TB at the health centers and
linked to care if TB is diagnosed. Among the new diagno-
ses, those who are eligible (Fig. 2) will be trained to become
recruiters to find and refer other presumptive TB cases to
the health centers in a snowball approach. The research
team will work with staff at the health centers to facilitate
screening and enrollment of recruits who are diagnosed
with TB to care. Eligibility criteria for lay counselors, seeds,
and recruiters are illustrated in Additional file 1.
All presumptive TB cases referred by seeds and re-
cruiters will be screened by lay counselors using a symp-
toms screening questionnaire [17]. The screening for
symptoms compatible with TB includes a cough lasting
for at least 2 weeks, hemoptysis, fever, weight loss, and
night sweats [17]. Presumptive TB cases and their symp-
toms screening questionnaire will be assessed by a nurse
practitioner in the health center for further TB work-up.
Those who are presumed to have TB will be asked to
submit sputum samples at the health center for acid-fast
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bacilli examination. Sputum samples of KAPs will be
assessed using the GeneXpert system at the referral hos-
pital laboratory. For non-KAPs, direct smear microscopy
will be undertaken at the nearest laboratory. If the spu-
tum examination results are negative, further assess-
ments and diagnosis of TB will be made on clinical and
radiological grounds by clinicians. TB screening and
treatment will be provided at the health facilities at no
cost to the patient, in accordance with the policies of the
NTP. Cases suspected of extrapulmonary TB (presence
of local and general symptoms [23]) will be referred to
the OD referral hospital for further assessment and diag-
nosis. We will follow-up all people with TB referred by
seeds for 6 months from the treatment initiation.
Intervention 2: ACF targeting household and
neighborhood contacts In this arm (Fig. 3), community
health volunteers will recruit household contacts of
people with TB and TB survivors diagnosed in the pre-
ceding 2 years. Immediate neighbors (10 nearest house-
holds) of the index cases (people with TB) who are
symptomatic will also be invited by the community
health volunteers to the screening session. Other KAPs
for TB and presumptive TB cases in the community en-
countered by the community health volunteers will also
be invited to the screening session.
The one-off screening session will be held at all of the
health centers in the selected ODs on specific days. Pre-
sumptive TB cases will be screened for TB symptoms on-
site, and CXR will be taken. Sputum samples from pre-
sumptive TB cases exhibiting features suggestive of TB
(on CXR and/or presence of TB symptoms) will be col-
lected for GeneXpert testing. Test results will be commu-
nicated to the newly diagnosed people with TB, and they
will be referred to the health centers for treatment and
follow-up. Should the health center of their choice not fall
Fig. 2 Active case finding with a seed-and-recruit model. A network is built by seed, as illustrated by the dotted lines in the left panel. The
network is expanded in a snowball fashion by recruiters who will be trained to recruit other people who might have tuberculosis (TB) in the
community. We refer key populations for TB in this study to people aged 55 and above, people with diabetes, people living with HIV, household
contacts of TB patients, and people who use and inject drugs. For GeneXpert test, one sputum specimen will be collected. For smear microscopy,
three sputum specimens will be collected at three different times, over 2 days
Teo et al. Trials          (2020) 21:220 Page 5 of 15
within the selected sites, follow-up (for the follow-up sur-
vey) will be conducted via telephone calls. Cases suspected
for extrapulmonary TB will be either diagnosed on-site or
referred to the referral hospital for further assessment if
needed. We will follow-up on all cases found in this arm
for 6 months from the start of TB treatment.
Intervention 3: ACF targeting the older population
(people aged ≥ 55 years) using mobile screening units
In the intervention clusters (Fig. 4), an outreach team
will conduct training and sensitization of the target
population prior to the screening session. We will set up
a screening site at a designated time, day, and place.
Communities in the districts will be informed of the
schedule for a one-off mass screening session before the
screening day. Each person who visits the screening ses-
sion will be screened and surveyed at registration by
trained staff. Information on their age, demographics,
and presence of TB symptoms will be collected. CXR
will then be performed on-site for all persons exhibiting
TB symptoms, and all individuals aged ≥ 55 years re-
gardless of symptoms. CXR will be assessed by trained
CXR readers on-site. When features suggestive of TB
are found, sputum samples will be collected for GeneX-
pert testing on-site as well. Test results will be commu-
nicated to the participants immediately or via telephone
calls, and people with TB will be referred for treatment
and follow-up at the health center where screening is
conducted or a health center of their choice. TB treat-
ment and care at the health center will be provided ac-
cording to the guidelines of the NTP. Should the health
center of their choice not fall within the selected sites,
follow-up will be conducted via telephone calls. Cases
suspected for extrapulmonary TB will be referred to the
Fig. 3 Active case finding targeting household and neighborhood contacts. This model targets household and neighborhood contacts of people
with TB. The village health support group will conduct contact tracing and case finding activities in the community before inviting the target
groups to the health center for TB screening and diagnosis. For GeneXpert test, one sputum specimen will be collected. HIV human
immunodeficiency virus, TB tuberculosis
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referral hospital for further assessment and diagnosis. A
follow-up will be conducted 6 months from treatment
initiation. The standard operating protocol of mobile
screening sessions depicts that the intervention will only
be conducted at the selected sites once in 1–3 years.
Criteria for discontinuing or modifying allocated
interventions
Since the interventions implemented in this study will be
part of standard procedures endorsed by the NTP in
Cambodia, the activities will not adversely affect the wel-
fare of the participants and pose no more than minimal
risk. Therefore, we do not foresee discontinuation or
modification of allocated interventions. In this study, par-
ticipation in the activities will be voluntary and the partici-
pants can withdraw from the study at any point in time.
Strategies to improve adherence to interventions
In this study, the implementing organizations will design
and ensure that the interventions’ (TB case-finding) pro-
tocols are strictly adhered. The medical procedures and
laboratory tests (e.g., GeneXpert, CXR, and sputum mi-
croscopy) conducted in this study are in accordance with
the national TB guidelines. In addition, the National
University of Singapore, which is not an implementing
organization, will conduct regular field visits and interim
analyses to ensure adherence to study protocol.
Relevant concomitant care permitted or prohibited
during the trial
No concomitant care would be specifically permitted or
prohibited during the trial due to the pragmatic nature
of the study. Interventions will be conducted at the com-
munity level according to standard operating procedures
in a “real-world” setting.
Provisions for post-trial care
Post-trial care will be provided in accordance with the
standard care as defined in the national TB guidelines
under the purview of the NTP.
Outcomes
We will measure the following endpoints in all four
arms. The primary endpoint will be the case notification
rate in the intervention and control ODs during the
study period. We define a TB case to be either bacterio-
logically confirmed (smear-positive identified by smear
microscopy, culture, or rapid diagnostics approved by
Fig. 4 Active case finding targeting the older population (people aged 55 and above) using mobile screening units. In the pre-mass screening
stage, program staff will invite the target population (people aged 55 and above) and other presumptive TB cases in the community to a roving,
one-off active case finding day at the health centers or other public sites in the community such as the pagoda. For GeneXpert test, one sputum
specimen will be collected. TB tuberculosis
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the World Health Organization (WHO)), smear-negative
TB (two sputum samples tested negative and clinically
diagnosed by a clinician—with abnormal CXR or no im-
provement in response to a course of broad-spectrum
antibiotics), or extrapulmonary TB (presence of local
symptoms such as enlarged lymph nodes, joint swelling,
and Gibbus deformity and presence of general symptoms
such as cough, fever, weight loss, and night sweats) [23].
This will be ascertained from the results of the screening
and routine case notification data reported to the NTP.
We will also determine: additionality, comparing the
yield in each arm with its respective historical baseline
(same period in the preceding year); and cumulative
yield over the project implementation period. Secondary
endpoints will include: the number of people needed to
screen to detect one TB case; direct and indirect costs
per TB case notified; and the treatment outcome of all
people with TB in this study. These data will be col-
lected on the aggregated form at the health center level
or as reported by the project implementation team in
each arm, except cost data, which will be collected from
study participants in the baseline and follow-up surveys.
Participant timeline
The participant timeline is presented in Table 1.
Sample size
Simulations were conducted to estimate the power of
the trial to detect a statistically significant difference be-
tween the intervention arms and the control arm for the
primary outcome of the trial. To develop a basis for
these simulations, we examined the ranges and variabil-
ity of effect sizes from previously collected data that in-
cluded operations data from CATA, CENAT, KHANA,
and the NTP annual TB report 2018 [28]. We defined
effect size as the percentage increase in the number of
cases notified to the NTP because of the intervention
(baseline: PCF). CATA, CENAT, and KHANA have
Table 1 Schedule of enrollment, implementation of interventions, assessments, and data collection for the period of the trial
Timepoint Study period
Enrollment Allocation Post-allocation
2019 2019 2019 2020 2020 2020 2020 2021 2021
Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Enrollment (cluster level)
Assessment of cluster X
Randomization of cluster X
Allocation of intervention X
Interventions
Active case finding with
a seed-and-recruit model
X X X X X
Active case finding targeting
household and neigh
borhood contacts
X X X X X
Active case finding targeting
people aged 55 years and older
using mobile screening units
X X X X X
Passive case finding X X X X X
Assessments (cluster level)
TB case notification by
selected clusters
X X X X X
TB cases reported by
each arm
X X X X X
Individuals screened for TB X X X X X
Treatment outcomes X X X X X
Cost data X X X X X X X
Assessments (individual level)
Enrollment X X X X X
Baseline survey X X X X X
Follow-up survey X X X X X
TB tuberculosis, Q quarter
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implemented the respective interventions (different strat-
egies of ACF) at different sites in Cambodia between 2017
and 2018. The percentage of estimated additional cases no-
tified to the NTP by CATA, KHANA, and CENAT during
the intervention period (scenario 1) was 110%, 98%, and
30%, respectively. For this scenario, the power was over
90%. We also considered three more sets of conservative
effect sizes: (scenario 2) assuming all intervention arms
have an effect size of 75%; (scenario 3) assuming all inter-
vention arms have an effect size of 50%; and (scenario 4)
assuming all intervention arms have an effect size of 25%.
There was a similar level of power for a more cautious esti-
mate (scenario 2—a 75% improvement in case notifica-
tion). In scenarios 3 and 4, the power was maintained
above 70% that a difference between intervention and con-
trol arms could be detected.
Recruitment
The trial will be conducted at the selected ODs, and all
communities and individuals who are eligible will be in-
vited to participate in the activities.
Assignment of interventions: allocation
Sequence generation
The unit of randomization will be the ODs (clusters).
From the list of underserved ODs in Cambodia provided
by CENAT, we will randomly allocate four ODs with
high TB incidence and four ODs with low TB incidence
to the intervention and control arms, matched by the
population size and the number of health centers.
Concealment mechanism
Randomization will be performed by a person who will
not be otherwise engaged in the project and will be
blinded to the identity of the districts. Project coordinators
and residents in the selected ODs will not be masked to
the intervention. All case-finding activities share the same
objective—to find TB cases—and they will be done with-
out reference to the intervention group.
Implementation
The population living in the selected ODs will be in-
cluded in the respective cluster. There will be four arms
(Fig. 1), and two clusters will be randomly allocated to
each arm. As all interventions have been endorsed by
the CENAT and conducted in Cambodia, participants
will not be notified if they are part of the intervention or
the control group.
Assignment of interventions: blinding
Who will be blinded
The data analysts will be masked to intervention alloca-
tion and will only analyze de-identified data.
Procedure for unblinding if needed
This pragmatic cluster randomized trial is open-
label, where project coordinators and staff are not
blinded. All case-finding activities will be imple-
mented in the selected sites, as indicated. Study par-
ticipants and health center/laboratory staff will not
be notified if they are part of the intervention group
or the control group. Therefore, unblinding will not
occur in this trial.
Data collection and management
Plans for assessment and collection of outcomes
For the primary endpoints, we will collect case notifica-
tion data from the intervention implementers (CATA,
KHANA, CENAT), the provincial health department,
and health centers (Table 2). For the secondary end-
points, data on treatment outcomes will be collected
from the health centers. To assess the number needed to
screen, we will collect screening data and the number of
TB cases diagnosed from the intervention implementers,
the provincial health department, and health centers.
Data on costs—direct and indirect medical costs [29,
30], intervention, diagnostics, and medications—will be
collected from the intervention implementers and the
baseline and follow-up surveys (Table 2). In the survey,
we will document the baseline characteristics of new
diagnoses found in all arms using a questionnaire. Infor-
mation on age, gender, education level, occupation,
number of family members and housing, smoking, alco-
hol use, drug use, TB history, and the presence of other
comorbidities will be collected. We will adapt and
contextualize the knowledge, attitude, and practice sur-
vey instrument tools developed by the WHO to collect
information on TB knowledge, attitudes, and care-
seeking behavior toward TB [31]. A short follow-up sur-
vey will be conducted at the end of the TB treatment
period for each person with TB to collect information
on missed doses, side effects, and other TB treatment-
related costs incurred.
Data collectors (project staff from CATA, CENAT,
KHANA, and/or health center staff) will be trained to
explain the study to the participants, obtain written con-
sent for the surveys (Additional file 2), and administer
the questionnaire. The data collectors will brief partici-
pants on the nature and purposes of the study and po-
tential risks, and will highlight that information will be
kept confidential. Consent for the surveys will be taken
by the data collectors in a private space after
randomization.
Data collectors will administer the questionnaire (both
questionnaire 1—baseline survey and questionnaire 2—
follow-up survey) on-site using a tablet-administered
format. The baseline survey will take between 30 and 40
min to complete, and the follow-up survey will take
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approximately 30 min to complete. The surveys may be
conducted via telephone calls for participants who are
unable to visit the health centers for interviews. Refusals
will be excluded from this study, but consent will be
sought to record demographic characteristics (partici-
pants would only be completing the “Socio-Demograph-
ics” section of the questionnaire if they have signed the
Consent Form indicating consent to participate in the
study but later choose not to complete the question-
naire). Participants will be reimbursed USD 2 for their
participation at baseline (questionnaire 1) and USD 2 for
an exit interview (questionnaire 2) at the end of the 6-
month follow-up.
Plans to promote participant retention and complete
follow-up
The plans to promote participant retention and to man-
age refusals are illustrated in the previous section “Plans
for assessment and collection of outcomes”.
Data management
Data coding, quality control, and data entry will be done
following established procedures at KHANA and Saw
Swee Hock School of Public Health, National University
of Singapore. A database will be developed for data entry
in KoBoToolbox [32], which includes a built-in range,
and within and between-variable consistency checks.
Table 2 Endpoints and data collection
Study endpoint Description Data source
Primary endpoints
Case notification rates
(cases notified per 10,000
population per year)
Numerator: number of
cases notified by the
selected districts
Case notification
data from CENAT
Denominator: total
population in the OD
Population statistics
(Ministry of Planning/Department
of Statistics/CENAT)
Additionality (additional
number of cases reported
compared to historical baseline)
Number of cases notified
by the selected districts
Case notification data from CENAT
Historical data (cases
notified in the
preceding 3 years)
Historical case notification
data from CENAT
Cumulative yield
(cases diagnosed per
1000 screened)
Numerator: number of
cases reported by each arm
Program data
In the control arm, data to
be collected from the health
centers monthly
Denominator: total number
of individuals screened
Program data
Provincial health department
laboratory data to determine
the number of people screened
at health centers in the control arm
Secondary endpoints
Treatment outcomes TB treatment outcomes of
all new patients 6 months
after treatment initiation
Health centers
Number needed to
screen
Numerator: total number
of individuals screened
Program data
Provincial health department
laboratory data to determine
the number of people screened
at health centers in the control arm
Denominator: number of
cases reported by each arm
Program data
Control arm: data to be collected
from the health centers monthly
Cost per TB case
diagnosed/notified
Direct and indirect medical
costs while seeking care for TB
Staff and intervention costs
Diagnostics and medication costs
Health-care-seeking costs: data to
be collected in the baseline and
follow-up survey
Intervention costs: data to be
collected from KHANA, CENAT,
and CATA
DALYs: data to be extracted from
WHO global burden of disease studies
and other existing literature
Incremental
cost-effectiveness ratio
per DALY averted
CATA Cambodia Anti-Tuberculosis Association, CENAT National Center for Tuberculosis and Leprosy Control, DALY disability-adjusted life year, OD operational
district, TB tuberculosis, WHO World Health Organization
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The program also runs error-checking applications and
produces reports of inconsistencies to be checked daily.
The database will be exported into Excel to check for
consistency and to clean before data analyses. All data
will be entered into the database within 1 month of col-
lection. For baseline data, a precoded questionnaire will
be used to minimize data coding errors. All data forms
and questionnaires will be checked for errors by the field
supervisors, and necessary corrections will be made dur-
ing data entry.
Confidentiality
The steps taken to maintain participants’ confidentiality
during the consent-taking process are illustrated in the
earlier section “Who will take informed consent?”. Fur-
thermore, only project staff from CATA, CENAT, and
KHANA will have access to the personal data in the
trial. These data will not be published, and they will be
discarded after the publication of results.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use
This trial will evaluate four models of case detection to
reach people with TB who are undiagnosed effectively.
The collection and evaluation of sputum samples and
other biological specimens in the course of this trial for
the diagnosis and management of TB will be conducted
following the standard protocol and guidelines in
Cambodia [23]. It is not within the scope of this study to
conduct additional analyses on the biological specimens
collected. Hence, the management of biological speci-
mens collected in the course of this trial will be under
the purview of the NTP as they would normally be han-
dled outside the research.
Statistical methods
Statistical methods for primary and secondary outcomes
For the primary endpoints, we will compute TB case noti-
fication at the cluster level by dividing the total number of
TB cases (all forms) notified by the selected ODs by the
total population in each OD. Case notification rates will
be presented as TB cases notified per 100,000 population
per year. The difference in the total number of TB cases
notified during the intervention period and the number of
TB cases notified in the preceding 3 years will be com-
puted to determine additionality. We will calculate the cu-
mulative yield of TB cases by dividing the number of cases
notified in each arm by the total number of people
screened for TB. Cumulative yield will be presented as TB
cases notified per 1000 individuals screened.
For the secondary endpoints, we will evaluate the treat-
ment outcome of TB cases detected in this study accord-
ing to the following categories: treatment completed
(without evidence of failure); treatment failed (sputum
smear remains positive at month 5 or later of treatment);
died (death due to any reasons before and during treat-
ment); lost to follow-up (people newly diagnosed with TB
who do not initiate treatment or treatment course that is
disrupted for 2 or more successive months); not evaluated
(no treatment outcome data available); and cured (sputum
smear converted from positive to negative in the final
month of the treatment and on at least one earlier assess-
ment at month 2 or month 5) [23]. The number needed
to screen to detect one TB case in each arm will be calcu-
lated by dividing the total number of persons screened by
the number of TB cases detected (i.e., the reciprocal of the
absolute cumulative yield). Direct and indirect medical
costs that will be incurred before and during health-
seeking will be measured based upon the baseline and
follow-up questionnaires. Costs for identification of pre-
sumptive TB cases and engagement with KAPs for screen-
ing, including training and meetings before initiating ACF
activities, will be categorized separately from the costs for
diagnosis using radiological/bacteriological means and
management of people with TB. The incremental cost-
effectiveness ratio (ICER) will be estimated by dividing the
difference in total costs between trial arms by the differ-
ence in the total number of TB cases detected. The ICER
per disability-adjusted life year averted will also be consid-
ered as a benchmark to determine whether the interven-
tions are cost-effective.
We will analyze the primary and secondary endpoints
by intention to treat, and the analyses will be conducted
in two stages. First, we will analyze and present primary
and secondary endpoints using the cluster summary
method. The baseline characteristics of all arms at the
cluster level and individual-level characteristics at base-
line and endline will be compared using Student’s t test
and hierarchical or mixed-effect models to estimate the
ratio of these means. As the ODs have several health
centers, we will adopt a linear mixed-effects model
adjusting for baseline measurements to account for clus-
tering in the data. Individual-level data will also be in-
corporated into multivariable regression models to
account for potential confounders differing by the trial
arm and improve the precision of the risk ratios by ac-
counting for intercluster variations. The impact of TB
case-finding strategies on treatment outcomes will be
evaluated using survival analysis to compare treatment
success rates across the intervention and control arms.
The study will be reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT) [33]
statement (Additional file 3), the template for interven-
tion description and replication (TIDieR) [34] checklist
for intervention description and replication (Additional
file 4), the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) [35] statement
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(Additional file 5), and the Pragmatic Explanatory Con-
tinuum Indicator Summary-2 (PRECIS-2) [36] for prag-
matic trials (Additional file 6). All statistical analyses will
be conducted using STATA 14 (Stata Corp LP, TX,
USA) and R (R Foundation for Statistical Computing,
Vienna, Austria).
Interim analyses
Interim analyses will be conducted by the data analyst
who is otherwise masked to intervention allocation.
Methods for additional analyses (e.g., subgroup analyses)
The baseline characteristics of participants in all arms at
the cluster level and individual-level characteristics at
baseline and endline will be compared using Student’s t
test and hierarchical or mixed-effect models to estimate
the ratio of these means. As the ODs have several health
centers, we will adopt a linear mixed-effects model
adjusting for baseline measurements to account for clus-
tering in the data. Individual-level data will also be in-
corporated into multivariable regression models to
account for potential confounders differing by the trial
arm and improve the precision of the risk ratios by ac-
counting for intercluster variations.
Methods in analysis to handle protocol nonadherence and
any statistical methods to handle missing data
We will adopt intention-to-treat analyses, and imput-
ation methods will be considered in the event of missing
data.
Plans to give access to the full protocol, participant-level
data, and statistical code
Information from the full protocol will be published in a
peer-reviewed journal. The relevant data analyzed during
the development of this study protocol are available
upon request from the corresponding author.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee
The coordinating center will be based in the KHANA
Center for Population Health Research. The steering
committee will comprise representatives from CATA,
CENAT, KHANA, and Saw Swee Hock School of Public
Health, National University of Singapore. Data will be
managed by the team at KHANA, with inputs from the
other two implementing organizations. The research
team from Saw Swee Hock School of Public Health, Na-
tional University of Singapore will be responsible for the
analyses of the data from the trial. The steering commit-
tee will adjudicate the endpoints and develop the find-
ings dissemination plan in consultation with the data
monitoring committee.
Composition of the data monitoring committee, its role,
and the reporting structure
The data monitoring committee (DMC) will comprise
representatives from KHANA Center for Population
Health Research and Saw Swee Hock School of Public
Health, National University of Singapore. The DMC will
be formed independently from the funders. The DMC will
be responsible for the independent assessment of the val-
idity and integrity of the pragmatic cluster randomized
controlled trial. Interim analyses will be presented to the
DMC. The DMC will report trial progress and the results
of the trial steering committee. The DMC will meet twice
a year, or more if needed.
Adverse event reporting and harms
There are no major perceivable risks in this study. The
potential psychological distress because of the questions
that the study poses is minimal. Participation is purely
voluntary, and the decision to not participate in this
study or to terminate their participation at any point
during the study will not have any negative conse-
quences. All participants and those who refuse to par-
take in the survey will not be deprived of the standard
care they ought to receive for TB. As the interventions
we are evaluating are operations that have been imple-
mented and endorsed by the NTP, the risks have been
thoroughly deliberated. The interventions involve only
models of care to reach people with TB. TB screening,
diagnosis, and treatment algorithms included in these
models are per standard protocol in Cambodia.
Frequency and plans for auditing trial conduct
The research team will conduct at least two monitoring
visits to each OD during the 1-year implementation
period. Field supervisors will also conduct at least four
monitoring visits (e.g., every quarter for KHANA arms
where the intervention is spread over 1 year and at every
screening session conducted by CATA and CENAT dur-
ing the implementation period, respectively). During
monitoring visits, we will review consent forms, com-
pleteness of the data collection forms, and compliance
with the trial protocol. Any anomalies in recruitment
and data will be followed up by the field staff. Interim
analyses will be conducted by the data analyst who is
otherwise masked to intervention allocation. Data, re-
cruitment processes, and interim results will be moni-
tored by the research team and reported to the DMC.
Plans for communicating important protocol amendments
to relevant parties (e.g., trial participants, ethical
committees)
Amendments to the protocol will be duly communicated
to all relevant parties, including the NTP and all
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partners, investigators, ethics boards in Cambodia and
Singapore, the trial registry, and journals.
Dissemination plans
We will share the findings from this study in results dis-
semination meetings with key stakeholders and peer-
reviewed journals. Findings from this trial could also po-
tentially inform ACF strategies in other countries with a
high TB burden.
Discussion
In partnership with CATA, CENAT, and KHANA, this
pragmatic cluster randomized controlled trial seeks to
examine the effect of community-based ACF strategies
in increasing TB case detection and its impact on treat-
ment outcome. This trial focuses on the ACF ap-
proaches, which are currently adopted as one of the
mainstay strategies to promote early TB diagnosis in
Cambodia [37, 38]. We will undertake a pragmatic ap-
proach [39] by testing existing interventions against
usual care (PCF) in a setting where these interventions
have been previously conducted to enhance
generalizability and replicability in Cambodia and other
similar settings in the future.
KAPs at risk for TB, such as people living with HIV,
close contacts of people with TB, and persons aged
55 years and older [18], are often those with limited ac-
cess to health care, leading to a delay in TB diagnosis
and poor clinical outcome [40] and further transmission
of the infection in the community [41]. Therefore, the
prioritization of high-risk groups for systematic screen-
ing of TB has been identified as a key component in the
global efforts to end TB [26]. However, ACF activities
can be costly [42], and a rigorous assessment of cost-
effective ACF strategies is therefore a critical justification
for TB control program planning and scale-up in a high-
burden, often resource-poor setting. Also, the imple-
mentation of this project will complement TB control
programs in Cambodia by expanding ACF to ODs that
are currently not served by CENAT, and other imple-
menting organizations, thus rendering operation and
strategic benefits to the country’s efforts to find undiag-
nosed TB cases in the community. It will also contribute
to the capacity-building of local staff in research.
An important foreseen limitation of our study is that we
will not be able to determine the impact of ACF on the
prevalence of TB in Cambodia. However, we believe that
the primary and secondary endpoints of this study will
generate an evidence base that is relevant to Cambodia
and generalizable beyond this research setting.
This project is congruent with the global plan to end
TB [43] by informing sustainable and evidence-based so-
lutions for TB control in Cambodia. Upon completion of
this trial, the results will inform and enable a nationwide
scale-up of an effective intervention that is contextual-
ized and complies with the principles set by the NTP to
find undiagnosed cases and control TB in Cambodia.
Trial status
Protocol version 1, December 3, 2019. Recruitment
began on December 18, 2019 and will be completed by
approximately December 31, 2020.
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Additional file 6. PRECIS-2 scores for trial domains.
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